Novartis Feb 14, 2023 Fusion Pharmaceuticals to Acquire Prostate Cancer Radiopharmaceutical Program From RadioMedix Feb 1, 2023 Novartis' Oncology Drugs See Solid Growth in Q4 2022 Premium Jan 10, 2023 JP Morgan Healthcare Conference, Day 1: Novartis, Bristol Myers Squibb, Mirati, Johnson & Johnson Jan 4, 2023 Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Dec 30, 2022 Top 10 Precision Oncology Stories in 2022: Liquid Biopsy, Radioligands, HER2-Low, Data Sharing Dec 13, 2022 Novartis' Pluvicto Approved in Europe for PSMA-Positive Castration-Resistant Prostate Cancer Dec 8, 2022 Adding Ibrance to Fulvestrant Doesn't Benefit CDK4/6 Inhibitor-Refractory Breast Cancer Patients Premium Dec 7, 2022 Kisqali Outperforms Combination Chemo in Aggressive HR-Positive, HER2-Negative Breast Cancer Premium Dec 5, 2022 Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting Nov 21, 2022 Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial Nov 17, 2022 Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators Nov 10, 2022 CAR T Cells Targeting CD19, CD22 Yield Encouraging Responses in Children With Leukemia Premium Nov 2, 2022 AmplifyBio Hoping to Lure Cell and Gene Therapy Clients With Newly Acquired Characterization Tech Premium Oct 25, 2022 Pluvicto Sales Ramp up, Kisqali Gains Continue in Q3 for Novartis Premium Oct 21, 2022 PSMA, Tumor Metabolic Volume May Help Refine Pluvicto Use in Prostate Cancer, Study Suggests Premium Oct 19, 2022 UCLA Researchers Suggest Simple Metabolic Biomarker May Predict CAR T-Cell Toxicities Premium Oct 14, 2022 EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC Oct 12, 2022 Mayo Clinic, Eclipse Launch Nucleus RadioPharma With $6M in Seed Financing Oct 4, 2022 Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
